Our Board

Carl L. Whatley, Jr.

CEO, Co-Founder and Chairman of the Board

Carl Whatley is a 43-year veteran of the pharmaceutical business, possessing vast experience in both the generic and branded business.

  • He began his career in 1980 as a sales representative with Wyeth (now Pfizer).

  • After a successful 21-year stint with Wyeth, he began his entrepreneurial adventures with the founding of ProEthic Laboratories LLC in 2001. ProEthic’s primary focus was branded prescription products, and in 2008, ProEthic was successfully divested to the Kowa Company Ltd.

  • In 2002, he also founded Midlothian Laboratories, focusing on the generic Rx market, and after a successful 6-year run, was divested to Hi-Tech Pharmacal. 

  • Carl continued to serve Kowa as its CEO & Chairman until his short-lived retirement in 2009.

  • In early 2010, he formed Cendalor LLC, a boutique management consulting and investment analysis firm serving the pharmaceutical, and medical food sectors.

  • Three years later he co-founded Vitruvias Therapeutics Inc., where he currently serves as Chairman & CEO.

  • Carl is a graduate of Auburn University at Montgomery, where he obtained a B.A. in history. 

Michael Altman

Director

Michael Altman joined Perceptive in 2007 and is a managing director on the investment team. His focus is on medical devices, diagnostics, digital health and Specialty Pharmaceuticals. He is also a member of the investment committee for the credit opportunities fund. Additionally, Michael serves as the CFO and Director of ARYA Sciences Acquisition Corp II & III. Prior to Perceptive he was a healthcare trader and analyst at First New York Securities. Michael graduated from the University of Vermont with a B.S. in Business Administration. Michael serves on the board of directors for Lyra Therapeutics, Nautilus Biotechnology, and Vitruvius Therapeutics.

Jason Wild

Director

Mr. Wild is the President and Chief Investment Officer of JW Asset Management, an SEC registered investment adviser with more than $500 million in assets under management. He is also the Executive Chairman of TerrAscend, a vertically integrated North American operator of cannabis cultivation, processing and retail distribution outlets. Mr. Wild also served as Chairman of the Board at Arbor Pharmaceuticals, Inc. until its divestiture to Azurity Pharmaceuticals in 2021. He is a graduate of the Arnold and Marie Schwartz College of Pharmacy where he received a bachelor’s degree in Pharmacy.

Ed Schutter

Director

Ed Schutter is a seasoned executive with over thirty-five years of pharmaceutical industry experience. He served as Chief Executive Officer of Arbor Pharmaceuticals, an Atlanta, Georgia based specialty pharmaceutical company until it’s acquisition in 2021. Prior to joining Arbor, Mr. Schutter served as President of Sciele (Shionogi) Pharmaceuticals. Prior to Sciele, he served as VP of Global Business development at Solvay Pharmaceuticals based in Basel, Switzerland. He has also held several senior management roles at the U.S. subsidiary of Solvay during his twenty years with the organization.

Mr. Schutter is a registered pharmacist with a BS in Pharmaceutical Sciences from Mercer University and an MBA from Kennesaw State University. He is currently a board member of TerrAscend, Vitruvias Therapeutics, and Establishment Labs (ESTA), and has been a previous board member of other public, private and nonprofit organizations.